Revenue jumped 56% to $1.2 million during the year, driven by collaboration agreements executed during the first half of 2018. Research and development expenses were $16.9 million for the year ended December 31, 2018, and $19.1 million for the comparable period in 2017.
ONTX shares ended its last trading session down 3.05% on Monday. The stock has declined 71% in the trailing 52 weeks, though it has bounced back this year.
READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS
CEO Steven M. Fruchtman said, “As we move through 2019, we anticipate continued progress across the Company, including recruiting for our Phase 3 IV rigosertib trial in second-line higher-risk MDS (HR-MDS) patients and advancing oral rigosertib in combination with azacitidine toward a pivotal phase 3 trial in first-line HR-MDS patients.”
The Pennsylvania-based firm on Monday said it had surpassed the 75% enrollment milestone in its pivotal Phase 3 trial of rigosertib for the potential treatment of high-risk myelodysplastic syndromes (HR-MDS), a study known as INSPIRE.
Full enrolment of 360 patients is anticipated in the second half of 2019.